title: Clinical Inquiries: Which drugs should post-MI patients routinely receive?
abstract: Patients should be placed on the following medications: antiplatelet agents, (meta-analysis for aspirin, multiple randomized controlled trials [RCTs] for aspirin plus clopidogrel); a statin; atorvastatin has the best evidence (a single RCT); a beta-blocker (meta-analysis); renin-angiotensin-aldosterone system blockers, whether or not the ejection fraction is diminished after myocardial infarction (MI) (SOR: A, meta-analysis for angiotensin-converting enzyme [ACE] inhibitor; B, single RCT for ACE inhibitor plus aldosterone blocker).
authors.forename: Victor
authors.initials: V
authors.lastname: Lin
authors.forename: John R
authors.initials: JR
authors.lastname: Holman
authors.forename: Barbara
authors.initials: B
authors.lastname: Jamieson
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D000069059:Atorvastatin; D000077144:Clopidogrel; D000077545:Eplerenone; D006538:Heptanoic Acids / Q000008:administration & dosage; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D013148:Spironolactone / Q000008:administration & dosage / Q000031:analogs & derivatives; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006538:Heptanoic Acids; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D013148:Spironolactone; D000077545:Eplerenone; D000069059:Atorvastatin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin